PROSTATE CANCER

This study tests a new way to treat prostate cancer using a single, high-dose radiation session aimed only at the tumor, not the whole prostate. For early-stage patients, this may be enough to cure the cancer. For higher-risk patients, the single session is followed by standard r…

This study is for men with prostate cancer that has spread to a few other parts of the body at diagnosis. It tests whether adding radiation therapy directly to those cancer spots (called metastasis-directed radiotherapy) can help keep the cancer under control longer than the usua…

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …

This study tests whether adding the experimental drug mevrometostat to the standard treatment enzalutamide can slow down cancer growth better than enzalutamide alone. It involves 1000 men with metastatic prostate cancer that still responds to hormone therapy. Participants will be…

This early-stage study tests BPX-601, a personalized CAR T cell therapy made from a patient's own immune cells, for advanced prostate cancer that has spread and stopped responding to other treatments. The trial will enroll 36 people to find the safest dose and check for side effe…

This study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while recei…

This study tests a personalized approach to radiation therapy for men whose prostate cancer has returned after surgery. Instead of giving everyone the same treatment, doctors will adjust the plan based on how well the cancer responds to initial radiation. Those who respond well m…

This study tests a program designed to help men with prostate cancer manage their heart health while undergoing hormone therapy (ADT). The program involves two counseling sessions with a nurse or physician assistant to educate about cardiovascular risks and how to reduce them. Re…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This Phase 3 trial tests whether personalizing apalutamide treatment based on cancer aggressiveness can reduce fatigue and other side effects in men with prostate cancer who have detectable PSA after prostatectomy. About 120 participants will receive either standard therapy or a …

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This study tests a special scaffold placed during prostate removal surgery to help men regain bladder control. About 266 men will be randomly assigned to get the scaffold or standard care. The goal is to see if the scaffold reduces urine leakage and improves quality of life over …

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in 300 men with metastatic prostate cancer that has progressed despite standard treatments. The goal is to check safety, find the right dose, and see if it can lower PSA levels, a marker of cancer…

This study tests a new drug called tinengotinib combined with standard hormone therapies (abiraterone or enzalutamide) in 50 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to usual treatment. The goal is to see if the combination i…

This study compares two treatments for low-to-intermediate risk prostate cancer: a new robotic surgery that removes part of the prostate through a single small incision, and high-intensity focused ultrasound (HIFU) that uses sound waves to destroy cancer cells. About 276 men will…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This study tests proton radiation therapy for men with prostate cancer that has returned or is at risk of returning after prostate removal surgery. Researchers want to see if this precise type of radiation can control the cancer while causing fewer side effects than standard radi…

This phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…

This study tests whether curcumin, a natural compound found in turmeric, can slow or stop the progression of low-risk prostate cancer in men who are not receiving immediate treatment. About 291 men with early-stage prostate cancer will take either curcumin or a placebo daily for …

This study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…

This phase 2 trial tests a combination of hormone therapy (Lupron), an androgen blocker (Darolutamide), and an immunotherapy (Pembrolizumab) given before and after prostate removal surgery in 40 men with high-risk prostate cancer. The goal is to see if this approach can reduce or…

This study tests whether giving radiation to the para-aortic lymph nodes (located in the abdomen) can better control prostate cancer that has returned in a limited number of spots. Men with hormone-sensitive prostate cancer and up to five lesions seen on a PSMA PET/CT scan will r…

This phase 2 trial is testing whether combining focal prostate ablation (a surgery that destroys only the cancerous part of the prostate) with a short course of hormone therapy can effectively treat intermediate-risk prostate cancer. The study will enroll 57 participants and meas…

This registry tracks 2,500 men with prostate cancer who receive Vanquish therapy, a procedure that uses water vapor (steam) to destroy cancerous tissue. The goal is to see how well it controls the disease and what side effects occur over time in real-world settings. Participants …

This study is testing a new type of radiation therapy for early-stage prostate cancer that delivers very high doses in just a few sessions. The radiation machine adjusts the beam daily based on the patient's anatomy, aiming to protect healthy tissue. Researchers will track qualit…

This study tests a procedure called irreversible electroporation (IRE) using the NanoKnife system to treat intermediate-risk prostate cancer. The goal is to destroy cancer cells with fewer side effects than standard treatments like surgery or radiation. About 100 men over age 50 …

This study tests a new treatment for people with metastatic breast or prostate cancer that has stopped responding to standard therapies. Participants receive infusions of their own immune cells that have been armed with a special antibody to help them find and attack cancer cells…

This early-phase study tests a new combination of two drugs that deliver radiation directly to prostate cancer cells. The goal is to find the safest dose that can be given together. About 42 men with advanced prostate cancer that has stopped responding to hormone therapy will tak…

This study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, s…

This Phase 3 trial tests whether adding a radioactive drug called AAA817 to standard hormone therapy can slow cancer growth better than current treatments alone. About 940 men with PSMA-positive metastatic castration resistant prostate cancer will be randomly assigned to receive …

This study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This phase 2 study is testing whether adding talazoparib to standard hormone therapy and enzalutamide can help men with prostate cancer that has spread to lymph nodes. About 30 participants will take the drug combination before having their prostate removed. The goal is to see if…

This study is testing a new drug called ADI-PEG20, which breaks down arginine (a nutrient cancer cells need), together with two chemotherapy drugs (carboplatin and cabazitaxel) in men with aggressive variant prostate cancer. The goal is to find the safest dose and check for side …

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the body's immune cells attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people t…

This study tests whether high intensity focused ultrasound (HIFU) can control prostate cancer that has come back after radiation therapy. About 25 men will receive one session of HIFU using the Focal One device. Researchers will check if the cancer remains absent in the treated a…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab, alone or combined with etrumadenant or tocilizumab, can boost immune cell activity in prostate tumors before surgical removal. About 68 men with localized prostate cancer will receive treatment before radi…

This study is testing a new way to give radiation for high-risk prostate cancer that has not spread. One hundred men will receive a shorter, stronger radiation boost to the prostate along with standard pelvic radiation. The goal is to see if this approach is safe and does not cau…

This study follows 700 adults with prostate cancer who have already received at least one dose of lutetium-177 PSMA-617 in earlier Novartis trials. Researchers will monitor long-term side effects such as dry mouth, eye dryness, bone marrow problems, kidney damage, and new cancers…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study tests a laser treatment guided by MRI to destroy early-stage prostate cancer in men aged 40-80 with low to intermediate risk. The goal is to control the cancer and avoid more aggressive treatments like surgery or radiation. Researchers will check results with follow-up…

This study looks at whether metformin, a drug used for diabetes, can help prostate cancer patients who have high blood sugar or are overweight. About 100 men will either take metformin plus get lifestyle advice, or just get lifestyle advice. The main goal is to see if it's possib…

This early-phase trial is testing a new treatment called A-CAR032 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer …

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This study tests whether freezing only the part of the prostate that contains cancer (focal cryotherapy) can control intermediate-risk prostate cancer. About 30 men with a single area of cancer will receive this targeted treatment. The goal is to reduce side effects while keeping…

This early-phase study tests whether combining a radioactive drug (177Lu-PSMA-617) with liver-directed procedures (ablation or chemoembolization) is safe for men with metastatic castration-resistant prostate cancer that has spread to the liver. The 30 participants must have alrea…

This study tests whether adding precise, high-dose radiation to cancer spots outside the prostate (called metastases) can help men whose prostate cancer has spread to just a few places. About 122 men with up to 5 metastatic spots will receive standard treatment plus either observ…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This early-stage study tests a new drug called AMG 509, alone or with other medicines, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check safety and how the body processes the drug. About 479 participants will…

This study tests a new drug called TRC003 for men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. TRC003 is a radioactive molecule designed to attach to prostate cancer cells and deliver radiation directly to…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This trial is testing a daily adaptive radiation therapy for low to intermediate risk prostate cancer that spares the urethra. The goal is to reduce urinary side effects compared to standard radiation. About 132 participants will receive this tailored radiation, and their urinary…

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This study tests an experimental drug called AAA817 in adults with a specific type of advanced prostate cancer (PSMA-positive) that has worsened after prior treatments, including a targeted therapy. About 443 participants will be randomly assigned to receive either AAA817 or the …

This study tests a precise radiation treatment (MR-guided high-dose-rate brachytherapy) for men whose prostate cancer has returned in the prostate bed after previous radiotherapy. About 20 participants will receive this targeted therapy to see if it can control the cancer with ac…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This study tests a new radioactive drug (lutetium rhPSMA-10.1) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose, and to see if it can shrink tumors or lower PSA levels. About 82 …

This early-stage trial is testing a drug called xaluritamig, given alone or with a hormone blocker, before men with intermediate- or high-risk prostate cancer have their prostate removed. The main goal is to see if the treatment is safe and does not interfere with surgery. About …

This study tests whether a precise type of radiation (SBRT) alone can control unfavorable intermediate-risk prostate cancer, avoiding the need for hormone therapy. About 215 participants will receive SBRT, with the radiation dose guided by a genetic test (Decipher) to personalize…

This study looks at men with high-risk prostate cancer that appears on only one side of the prostate. During robotic surgery to remove the prostate, doctors will either remove lymph nodes from both sides of the pelvis or just the side with cancer. The goal is to see if removing f…

This study tests whether adding a short, 30-day course of the oral hormone drug Relugolix to standard targeted radiation (SBRT) works better than radiation alone for men with intermediate-risk prostate cancer. About 60 men will be randomly assigned to one of the two treatments. T…

This study compares a shorter, high-dose radiation treatment (SBRT) to standard radiation for men whose prostate cancer has come back after surgery. About 284 men will be randomly assigned to one of the two approaches. The goal is to see if SBRT is as safe and effective, with few…

This early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This study tests whether a single, very high dose of precisely targeted radiation can safely treat intermediate-risk prostate cancer. About 200 men will receive one 24-Gy dose to the prostate, with a possible extra boost to the main tumor. Researchers will monitor side effects, q…

This trial tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to other treatments. The drug is designed to attach to prostate cancer cells and destroy them with radiation. The study aim…

This study tests whether eating 2 ounces of walnuts daily for 4-10 weeks can slow prostate cancer growth in 50 men scheduled for prostate removal. Participants are randomly assigned to add walnuts to their usual diet or stick with their normal eating habits. Researchers will meas…

This early-phase trial tests a new two-drug combination for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The drugs are REGN5678, which helps immune cells target cancer cells, and cemiplimab, which removes the br…

This phase 3 trial is testing whether taking aspirin and atorvastatin (a common cholesterol-lowering drug) can help men with castrate-resistant prostate cancer live longer. The study plans to enroll 1210 participants who are starting their first treatment for this advanced stage.…

This study tests a drug called REGN5678 in men with high-risk prostate cancer who will later have their prostate removed. The goal is to check the drug's safety and how it affects the cancer before surgery. About 42 men will take part in this early-phase trial at MD Anderson Canc…

This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Res…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metast…

This study tests a low-dose radioactive drug (177Lu-P17-088) that targets a protein called PSMA on prostate cancer cells. It is for people with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The goal is to see if the treatment can …

This early-stage trial tests a new treatment for men with localized prostate cancer. It uses a light-sensitive drug called verteporfin, which is injected into the bloodstream and then activated by laser light delivered through thin fibers placed into the prostate. The goal is to …

This study tests whether combining an experimental immunotherapy drug (SHR-1701) with targeted radiation can help men with metastatic castration-resistant prostate cancer, a form that no longer responds to hormone therapy. About 66 participants will receive either the drug plus r…

This study is testing a new, shorter radiation treatment for men with early-stage prostate cancer. Instead of the usual 5 sessions, doctors will give 3 high-dose radiation treatments. The goal is to see if this approach is safe and causes fewer side effects while still controllin…

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

This early-phase study tests a new drug called DXC008 in people with prostate cancer or other solid tumors (like Ewing sarcoma) who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Abou…

This phase 2 trial tests whether giving testosterone injections (bipolar androgen therapy) can delay the time it takes for prostate cancer to spread in men whose cancer is progressing despite standard treatment. About 69 men with non-metastatic castrate-resistant prostate cancer …

This study is for men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. It tests whether adding a targeted radiation drug (225Ac-J591) to immunotherapy (pembrolizumab) and an androgen-receptor inhibitor works better than the im…

This study looks at whether eating a controlled Mediterranean diet before prostate cancer surgery can improve health markers like insulin levels. Twenty men scheduled for prostate removal will receive pre-made meals and be monitored. The goal is to see if this diet is practical a…

This early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through th…

This study is testing a new drug called SHR-4394 combined with other anti-cancer treatments for men with prostate cancer. The goal is to find the safest dose and see if the combination can lower PSA levels, a key marker of prostate cancer. About 100 men aged 18 to 85 will take pa…

This study tests a daily herbal supplement called INM176 (made from Angelica Gigas Nakai) in 45 men with prostate cancer whose PSA levels are rising after prior treatment or who are on active surveillance. The goal is to see if the supplement is safe and can stabilize or lower PS…

This study compares a standard robot-assisted prostate removal surgery to a newer, pelvic fascia-sparing approach that aims to preserve nerves and support structures. Researchers will enroll 600 men with localized prostate cancer to see if the new technique offers similar cancer …

This study tests whether using a special PET scan (PSMA-PET) to guide radiation can reduce short-term side effects in men whose prostate cancer returns after surgery. About 54 men will receive targeted radiation to the pelvis plus a boost to spots seen on the scan, along with sta…

This study is testing ablative therapies—treatments that destroy cancer cells with heat or cold—for men with localized prostate cancer. Researchers want to see how well these treatments control cancer and affect quality of life, including urinary and sexual function. The study wi…

This study tests a combination of two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—in men with advanced prostate cancer that has stopped responding to hormone treatments. The goal is to see if this combo can slow or stop cancer growth. …

This study is for men with prostate cancer that has spread to pelvic lymph nodes only detectable by a special PSMA scan. It compares standard hormone therapy plus radiation to a stronger combination adding abiraterone and prednisone. The goal is to see if the stronger treatment i…

This study tests a new drug called 2141-V11, which helps the immune system find and kill prostate cancer cells. It is given as an injection into the tumor, either alone before surgery for intermediate-risk cancer or combined with hormone therapy for high-risk or early metastatic …

This study follows 100 men with prostate cancer who choose to have high-intensity focused ultrasound (HIFU) as their treatment. HIFU uses sound waves to heat and destroy cancer cells in a targeted area. Researchers will check if the cancer is gone at 6 and 18 months and track how…

This phase 3 trial is testing whether a shorter, more intense radiation treatment called SBRT works as well as the current standard of external radiation plus a brachytherapy boost for men with unfavorable-risk prostate cancer. About 710 participants will also receive hormone the…

This phase 2 trial tests Enhertu, a targeted drug, in 60 men with HER2-positive prostate cancer that has spread and stopped responding to hormone therapy and newer drugs like abiraterone. Participants must have tried or refused chemotherapy. The study measures tumor shrinkage and…

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …

This study tests whether adding omeprazole (a common heartburn medicine) to standard chemotherapy can help control advanced prostate cancer that has stopped responding to other treatments. About 50 men with castration-resistant prostate cancer will receive either omeprazole plus …

This study looks at whether proton therapy can safely treat cancers that return after standard radiation. Proton beams are more targeted than traditional X-rays, so they may deliver stronger doses to the tumor while sparing healthy tissue. Researchers will track side effects and …

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the…

This study tests two drugs—gedatolisib and darolutamide—together in men with metastatic castration-resistant prostate cancer (mCRPC), a type that has spread and no longer responds to standard hormone therapy. The first part finds the safest dose, and the second checks if the comb…

This study compares two treatments for men with intermediate-risk prostate cancer: focal HIFU (a targeted ultrasound that destroys only the tumor) and radical prostatectomy (complete removal of the prostate). The goal is to see which approach offers better value for money and qua…

This study for veterans with prostate cancer that has returned in a few spots (oligorecurrence) compares standard systemic therapy alone versus standard therapy plus PET-directed local treatment using surgery or radiation. The goal is to see if adding local therapy delays the can…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This study is testing whether adding a short, high-dose radiation boost to standard radiation therapy can safely improve treatment for men with unfavorable localized prostate cancer. The boost is delivered non-invasively using stereotactic body radiotherapy (SBRT), similar to a n…

This phase 3 trial compares two types of radiation therapy for men whose prostate cancer has returned after surgery. One schedule takes 5-6 weeks, while the other is completed in just 2 weeks. The study aims to see if the shorter option works just as well with manageable side eff…

This study tests two types of targeted radiation therapy (177Lu-PSMA-617 and 225Ac-PSMA-617) in 45 men with high-risk prostate cancer who are scheduled for prostate removal surgery. The goal is to see which therapy delivers more radiation to the tumor and how it affects the immun…

This study tests whether taking curcumin (a compound found in turmeric) after prostate removal surgery can help keep prostate cancer from coming back. About 650 men with early-stage prostate cancer who have had their prostate removed will take curcumin or a placebo. The main goal…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study tests a smarter way to give radiation to men whose prostate cancer has come back after surgery. Using advanced scans, doctors will give higher radiation doses to the spots where cancer is active and lower doses to healthy areas. The goal is to control the cancer while …

This clinical trial is for men with prostate cancer that has spread to nearby pelvic lymph nodes but not further. It compares two radiation strategies: one that gives a higher dose to the prostate only, and another that boosts both the prostate and the affected lymph nodes. All p…

The THUNDER trial is testing whether using advanced PET scans and a genetic test (Decipher) can help doctors choose the right treatment for high-risk prostate cancer. About 493 men will either get stronger treatment if their scans or genetic score show high risk, or less intense …

This study tests whether a 16-week supervised exercise program (circuit training with resistance, functional, and aerobic exercises) can improve frailty and muscle loss in 80 men with metastatic prostate cancer who are on hormone therapy. Participants must be pre-frail or frail. …

This study tests whether intensive cholesterol-lowering therapy can increase cancer-fighting immune cells in the prostate. About 140 men with prostate cancer who are under active surveillance will take a cholesterol-lowering drug for 3 to 6 months before a planned biopsy. The goa…

This study tests a new way to deliver radiation for intermediate-risk prostate cancer. Using an MRI machine that also delivers radiation, doctors can give a higher dose to the main tumor while lowering the dose to the rest of the prostate. The goal is to improve tumor control and…

This study tests whether giving a higher dose of radiation directly to the prostate (via HDR brachytherapy) can better control early-stage prostate cancer without causing too many side effects. About 36 men with low- or favorable intermediate-risk prostate cancer will receive one…

This study tests whether a new drug (BMS986365) combined with hormone therapy (degarelix) can safely shrink or eliminate high-risk prostate cancer before standard surgery. About 30 participants will receive the combination for several months, then have their prostate removed. The…

This study tests whether a family-centered program can help Black prostate cancer survivors and their caregivers eat better, be more active, and feel better overall. About 648 survivor-caregiver pairs will join, with some receiving the family program, some the survivor-only progr…

This study compares two types of radiation therapy (proton vs. photon) given after prostate removal surgery. The goal is to see if proton therapy causes fewer bowel problems and improves quality of life. About 900 men with prostate cancer will be randomly assigned to one of the t…

This study tests a surgical technique that grafts nerves to help men who have had lasting erectile dysfunction (ED) for over 18 months after prostate cancer surgery. About 100 men will receive the procedure and be followed for one year to see if their erections improve and if the…

This study tests whether using MRI scans to guide radiation can lower the dose to healthy parts of the prostate while targeting cancer spots. The goal is to reduce bowel-related side effects without losing cancer control. About 60 men with intermediate- or high-risk prostate canc…

This phase 2 trial tests whether taking simvastatin, a common cholesterol drug, for 8 weeks before prostate surgery can improve the immune system's ability to fight prostate cancer. Half of the 36 men with localized prostate cancer will receive the drug, while the other half will…

This study tests a precise type of radiation therapy (MRgRT) that aims to protect the nerves and blood vessels needed for erections in 70 men with low- or intermediate-risk prostate cancer. Participants receive 5 high-dose radiation sessions guided by MRI. The goal is to see if t…

This study tests whether adding a drug called relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 people whose cancer has not responded to standard treatments will take the study drugs for 24 weeks, then h…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This phase II study tests two experimental drugs, HS-20093 and SHR2554, combined with standard hormone therapies in 218 men with metastatic prostate cancer. The goal is to see if these combos are safe and can lower PSA levels or slow the cancer's spread. Participants must have ad…

This is a special, single-patient program for someone with prostate cancer who has run out of standard options. The treatment, called X-PACT, combines a drug called methoxsalen with a phosphor device and targeted X-ray energy to attack the tumor directly. The goal is to control t…

This study tests whether a compound from licorice root, called glycyrrhizin, can reduce PSA levels in men with prostate cancer before they have surgery to remove the prostate. About 60 men who are scheduled for prostate removal will take glycyrrhizin daily for a short time. The g…

This study looks at whether a special heart CT scan can find hidden artery plaque in prostate cancer patients who are on or about to start hormone therapy. About 100 participants will either get the scan or usual care. The goal is to see if the scan helps doctors prescribe better…

This study is testing a new treatment called [212Pb]Pb-ADVC001 for men with prostate cancer that has spread to other parts of the body. The treatment delivers a small amount of radiation directly to cancer cells. The study has two parts: first, finding the safest and most effecti…

This early-phase trial tests a drug called STM-416p that is given directly during surgery to remove the prostate in men with prostate cancer. The study involves 18 men and focuses on safety and finding the right dose. It is not yet testing whether the drug works better than stand…

This early-phase study tests a new drug called ASP5541 in Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments prednisone and hormone therapy. The main goals are to check the drug's safety and how it is processed by the…

This study is testing whether a single, high-dose radiotherapy session can safely control prostate cancer in men with intermediate or high-risk disease. About 58 participants will receive one focused radiation dose to the tumor, guided by MRI and imaging. The goal is to see if th…

This early-phase study tests a new way to deliver radiation implants (brachytherapy) for men with localized prostate cancer. By using advanced imaging (PET/CT and ultrasound) to map only the aggressive tumor areas, doctors hope to target the cancer while leaving healthy tissue un…

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This phase 2 trial is testing a new, shorter radiation plan for men with high-risk or unfavorable intermediate-risk prostate cancer. Participants receive a brachytherapy boost followed by just 5 sessions of whole-pelvis proton therapy. The main goal is to see if this approach is …

This phase 2 trial tests a new radiation approach for men with high-risk or locally advanced prostate cancer. It combines hypofractionated radiotherapy (fewer, larger doses) with a microboost that delivers extra radiation to the most aggressive tumor spots. The goal is to improve…

This phase 3 trial tests whether treating 1 to 10 metastatic tumors right away with precise radiation improves survival compared to waiting 3 months. It includes 800 adults with lung, colorectal, or prostate cancer that has spread to a few spots. Participants are randomly assigne…

This study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, for men with advanced prostate cancer. The drug lowers testosterone, which can help control the cancer. The study aims to find a safe dose and see how well men tolerate it, either…

This study is for men with high-risk prostate cancer that hasn't spread. It tests whether adding an immunotherapy drug (pembrolizumab) and a targeted drug (olaparib) to standard radiation therapy can better control the cancer. About 64 participants will receive the combination an…

This early-phase trial is testing a new way to deliver radiation for low-to-intermediate risk prostate cancer. Instead of many sessions, it uses just two high-dose treatments, with an extra boost to the main tumor. The goal is to see if this approach is safe and feasible for abou…

This study is testing whether adding a DNA vaccine (pTVG-AR) and immune checkpoint blockers (nivolumab or cemiplimab) to standard hormone therapy can improve outcomes for men with newly diagnosed, high-risk prostate cancer. About 60 participants will receive different combination…

This phase 2 trial is for men with unfavorable intermediate-risk prostate cancer. Participants choose between standard care (6 months of hormone therapy plus high-dose radiation) or radiation alone. The goal is to see if skipping hormone therapy still keeps cancer from returning.…

This phase II trial is testing whether using a special PET/MR scan (PSMA) to guide radiation therapy can improve outcomes for men with high-risk prostate cancer. Fifty participants will receive targeted radiation boosts to areas identified by the scan. The main goal is to see if …

This study tests a new radioactive drug called 225Ac-LNC1011 in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein (PSMA) on cancer cells to deliver radiation directly. Nine participants w…

This phase 2 trial is testing whether giving the targeted drug olaparib (Lynparza) along with hormone therapy for 6 months before surgery can shrink or eliminate prostate cancer in men with high-risk disease and specific gene mutations. About 32 men will receive the treatment, th…

This early-stage study tests a new drug called JANX007 in men with advanced prostate cancer that has spread and stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 272 men will take part across multiple centers.

This early-phase trial is testing an experimental oral drug called OCT-598 in 51 adults with advanced solid tumors, including breast, lung, and prostate cancers. The study aims to find the safest dose and see if the drug works alone or with standard chemotherapy. It is too early …

This study tests whether a 16-week, culturally tailored exercise program (aerobic and resistance training) can lower heart disease risk in Black men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). The study will enroll 62 participants, who w…

This study tests whether a shorter, more intense radiation treatment (5 sessions) is better than the standard 20-session approach for men with intermediate- or high-risk prostate cancer that hasn't spread. The goal is to improve cancer control while keeping side effects low. Abou…

This Phase 2 trial tests a sequence of three drugs—DFMO, high-dose testosterone, and enzalutamide—in 50 men with metastatic castration-resistant prostate cancer that has progressed on standard therapy. The goal is to see if this combination can lower PSA levels and delay cancer g…

This Phase 1 trial is testing TJ101, an experimental antibody-drug conjugate that delivers chemotherapy directly to cancer cells. It is for adults with advanced or metastatic solid tumors (lung, prostate, esophageal, and others) who have run out of standard options. The study aim…

This study looks at men whose prostate cancer has returned after surgery, with new spots found on only one side of the pelvis using a special scan. The goal is to see if removing lymph nodes only on that one side works as well as removing them on both sides, while causing fewer s…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This study tests a new drug called INR102, which delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial will check safety, how the drug moves through…

This phase 2 trial is testing whether a combination of targeted radiation (SBRT) and a radioactive drug called Pluvicto can control metastatic castration-resistant prostate cancer without the need for ongoing hormone therapy. Sixty participants will stop castration and receive th…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This study follows 130 men with metastatic prostate cancer who are receiving standard treatment with abiraterone and prednisone. Researchers want to see if a person's race or ethnicity influences how well the drugs work, by measuring PSA levels and looking at genetic differences.…

This study tests a new type of radiation therapy for prostate cancer that uses an MRI machine to guide the beam in real time. The goal is to deliver high doses of radiation more precisely to the tumor while sparing healthy tissue. The trial will enroll 50 men with localized or li…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This study tests whether men with low-volume metastatic prostate cancer can safely stop taking certain hormone drugs (apalutamide or enzalutamide) after 12 months, instead of continuing indefinitely. 400 men will be randomly assigned to either stop or continue therapy, with the o…

This phase II trial tests whether adding a radioactive drug called Lu-PSMA to precise radiation therapy can better control prostate cancer that has spread to just 1-3 spots. About 70 men with hormone-sensitive prostate cancer will be randomly assigned to get radiation alone or ra…

This phase 2 trial tests a combination of fasudil hydrochloride and an immunotherapy drug (tirapibep) in 30 men with metastatic castration-resistant prostate cancer that has progressed after standard treatments. Participants receive the drugs alongside standard hormone therapy ov…

This study tests a program that helps prostate cancer patients become more physically active. It combines a personalized exercise plan, coaching from a fellow patient who is already active, and support from a doctor. The goal is to see if this approach helps men stay active long-…

This Phase 2 trial tests whether adding homoharringtonine (a drug from a Chinese evergreen plant) to standard hormone therapy before prostate removal can improve outcomes for men with high-risk or advanced prostate cancer. About 93 participants will receive the drug combination b…

This study tests whether a personalized diet and exercise program is practical for 30 men with metastatic prostate cancer who are already receiving hormone therapy. The goal is to see if patients can stick with the program and if it helps control their cancer. The study does not …

This master trial is testing a new radiation technique called SMART, which uses MRI to guide and adapt radiation beams in real time. The goal is to deliver high doses precisely to tumors while protecting nearby organs. The study enrolls adults with various cancers (pancreas, lung…

This study tests whether giving the drug enoblituzumab for 12 weeks before prostate removal surgery can help prevent cancer from coming back in men with high-risk localized prostate cancer. About 219 men will be randomly assigned to receive either the drug or standard care. The m…

This study tests whether a 12-week exercise program can reduce the number of cancer cells in the blood of men with advanced prostate cancer. Twenty men who are already on hormone therapy will participate. The goal is to see if exercise can help control the disease, not cure it.

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This study is for people with a certain type of prostate cancer that is not too advanced but has some higher-risk features. It tests whether adding a short course of the drug darolutamide to standard radiation therapy can lower PSA levels to a very low target (0.1 ng/mL or less) …

This study is testing whether a new, shorter course of radiation therapy is safe and tolerable for men with unfavorable or higher-risk prostate cancer. It combines external beam radiation with a single internal radiation boost (brachytherapy). The trial will enroll 31 participant…

This Phase II trial is testing a drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have not responded to standard treatments. The study aims to find the best dose and see how well the drug shrinks tumors, while also monitoring safety and si…

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. About 52…

This study is for men with metastatic hormone-sensitive prostate cancer who have already been on hormone therapy for 6-12 months and have very low PSA levels. It compares two approaches: stopping and restarting treatment based on PSA levels (intermittent) versus staying on treatm…

This phase III trial tests whether adding radiation to the lymph nodes improves outcomes for men whose prostate cancer has returned after prostatectomy, indicated by a rising PSA. About 374 participants with low PSA levels will receive either standard radiation to the prostate be…

This study tests a combination of hormone therapy, chemotherapy, and targeted ultrasound for men with metastatic prostate cancer that has spread widely. The goal is to see if adding focused ultrasound to standard triple therapy can better control the disease. About 116 men will t…

This early-stage study tests whether injecting alcohol around the prostate can block nerve signals that may help cancer grow and spread. Twenty-one men with high-risk prostate cancer who plan to have their prostate removed will receive one or two injections before surgery. Resear…

This study tests whether a very short course of radiation (5 days) is as safe and effective as a longer course (2-3 weeks) for men with localized prostate cancer. All participants also receive a brachytherapy boost. The main goal is to compare side effects and quality of life ove…

This phase 3 study is testing whether adding a short course of hormone therapy (androgen suppression) to image-guided radiation therapy helps men with intermediate-risk prostate cancer. About 192 men will receive either radiation alone or radiation plus hormone therapy. The goal …

This study tests a new drug called HRS-1167 combined with two standard medications (abiraterone and prednisone) in men with metastatic prostate cancer. The goal is to see if the combination is safe, tolerable, and effective. About 66 participants will be enrolled across multiple …

This study is testing whether a radioactive tracer called 18F-DCFPyL, used during a PET/CT scan, can better detect where prostate cancer has returned in men whose PSA levels are rising after initial treatment. About 350 men will be followed for up to 5 years with regular scans an…

This study tests whether an artificial intelligence (AI) algorithm can help doctors decide where to take biopsy samples in men with prostate MRI findings that are not clearly cancerous. About 50 men with low-risk or uncertain MRI lesions and elevated PSA levels will be randomly a…

This study tests whether men with very high PSA and suspicious MRI can safely skip the painful 12-needle systematic biopsy and rely only on targeted samples. Over 1,200 men will get both biopsies, but each sample is analyzed separately to see how often the extra needles find dang…

This study investigates whether a blood test (liquid biopsy) can detect prostate cancer early by looking for tumor cells and genetic material in the blood. Researchers will compare blood samples from men with suspected prostate cancer to those without the disease. The goal is to …

This early-stage trial tests whether a special nanoparticle tracer can help surgeons see prostate cancer cells during surgery. Sixteen men with high-risk prostate cancer will receive an injection of the tracer, then undergo PET/MRI scans and surgery. The goal is to see if the tra…

This early-stage study tests a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal is to see if it is safe and can help detect cancer that has spread or come back. Participants receive one injection and then undergo PET scans to measure rad…

This study tests whether a newer biopsy method (perilesional biopsy) can find aggressive prostate cancers as well as the standard combination of targeted and systematic biopsies. About 640 men with a single suspicious MRI lesion will be randomly assigned to one of two biopsy appr…

This study compares two biopsy methods in 572 men who have multiple suspicious spots on MRI but have never had a prostate biopsy. One method combines targeted biopsy with a wider sampling around each spot (perilesional biopsy), while the other combines targeted biopsy with standa…

This study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, aggressive prostate cancer who are planning to have their…

This study compares a newer PSMA PET scan to the standard MRI for staging prostate cancer in men eligible for focal therapy (treatment that targets only the tumor). About 138 men with early-stage prostate cancer will be randomly assigned to get the PSMA PET scan or not. The goal …

This phase 2 trial tests whether a radioactive tracer called 64Cu-DOTA-AE105 can accurately show the aggressiveness of prostate cancer on a PET scan. About 168 men with low- to intermediate-risk prostate cancer will receive the tracer and undergo imaging. The goal is to see if th…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study tests a new microscope called LaserSAFE that scans the removed prostate during surgery to see if cancer cells are at the edge. If it works well, surgeons can decide right away whether to spare nearby nerves. About 693 men with prostate cancer will take part, and the st…

This phase 3 trial tests a new radioactive imaging agent, 64Cu-SAR-bisPSMA, to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer will receive a single injection of the agent before their scheduled prost…

This study is testing whether a special type of PET/CT scan (PSMA-PET CT) can accurately detect aggressive prostate cancer in men who are on active surveillance (watchful waiting). Researchers will scan 200 men with low- or favorable intermediate-risk prostate cancer at the start…

This study tests two advanced imaging techniques, PSMA PET/CT and MRI-RSI, against the standard MRI to see which finds and outlines prostate tumors most accurately. Fifty men with newly diagnosed, higher-risk prostate cancer will undergo all scans and a targeted biopsy. The goal …

This study tests a special dye that makes prostate cancer cells glow during surgery. About 22 men with aggressive prostate cancer will receive the dye before their prostate removal surgery. Surgeons will use a special camera to see the glowing cancer, helping them remove more of …

This early-phase trial is testing whether a special MRI scan, using hyperpolarized pyruvate and urea, can better detect high-grade prostate cancer that is still confined to the prostate. About 80 men scheduled for prostate removal will receive an IV of these substances before ima…

This early study tests a new radioactive tracer called 68Ga-FC516 in 10 healthy adults and people with prostate cancer. The goal is to see if it is safe and how well it finds tumors on PET/CT scans compared to existing tracers. The results will help improve prostate cancer diagno…

This study is testing new types of MRI scans to see if they can more accurately find and grade prostate cancer without using contrast dye. Researchers will compare these new scans with standard MRI results and tissue samples from surgery or biopsy. About 300 people with suspected…

This study tests a new software tool that automatically analyzes MRI images of the prostate to find cancer areas that doctors might miss. About 180 people with known or suspected prostate cancer will get an MRI and then a targeted biopsy. Researchers will compare the software's a…

This Phase 3 trial is testing whether a radioactive tracer called [18F]PSMA-1007 can improve PET/CT scans for men with newly diagnosed high-risk or very-high-risk prostate cancer. The goal is to see if it can more accurately detect cancer that has spread to pelvic lymph nodes. Ab…

This study is testing a new radioactive imaging agent called PSMA-T4 to see if it can safely and accurately find prostate cancer tumors. About 80 men with prostate cancer will receive an injection of PSMA-T4 and then have a special scan (SPECT/CT) to detect cancer lesions. The go…

This study tests a custom electrical impedance probe that measures tissue properties during prostate removal surgery. The goal is to see if it can instantly detect any cancer left behind, helping surgeons remove it all in one go. Two hundred men with prostate cancer will take par…

This study is testing whether a PSMA-PET scan using a radioactive tracer called 18F-rhPSMA-7.3 can accurately detect prostate cancer that has come back after focal gland treatment. About 70 men who had focal therapy for intermediate-risk prostate cancer will receive the scan, and…

This phase I/II trial tests a radioactive tracer called 64Cu-GRIP B, which targets granzyme B—a substance released by immune cells. By using PET scans, researchers hope to see immune activity in tumors and predict whether immunotherapy will work. The study involves about 91 adult…

This study tests a new way to decide who needs a prostate biopsy. Instead of relying only on MRI, it adds a blood test called Prostate Health Index (PHI) to better tell which men have dangerous prostate cancer. The goal is to safely skip biopsies in men with low-risk findings, re…

This study is testing whether combining a special PET scan (PSMA-PET) with artificial intelligence can help predict how prostate cancer will behave. Researchers will scan 1,000 men with prostate cancer and use deep learning to find patterns in the images that link to survival and…

This study is testing whether a new flexible MRI coil can accurately detect significant prostate cancer in 258 men with intermediate or high-risk disease. The goal is to see if this less invasive approach can reduce the number of unnecessary biopsies. Participants will receive bo…

This study tests whether adding a special MRI scan to the standard prostate exam is safe and can collect useful data. About 75 men aged 40-90 with elevated PSA levels will get up to 15 extra minutes of scanning. The goal is to see if the new platform causes any serious problems a…

This study is testing whether adding a special PET scan (using a radioactive tracer called flotufolastat F18) to the standard MRI can better find aggressive prostate cancer in men who are currently on active surveillance. About 120 men with low- or favorable intermediate-risk pro…

This study tests a robotic device that helps guide the ultrasound probe during prostate biopsies. The goal is to see if it can improve cancer detection and reduce errors compared to the standard freehand method. About 483 men scheduled for their first prostate biopsy will take pa…

This study is testing a new saliva-based DNA test called i4i PRODICT® that estimates a person's future risk of prostate cancer. Researchers want to see if men of Black African/Caribbean, South Asian, and White backgrounds aged 40-55 will take the test and find it acceptable. The …

This study tests whether a new type of PET scan (18F-DCFPyL PSMA-PET) can show prostate cancer lesions as well as the standard scan (68Ga-PSMA-11 PET/CT) in 30 men with advanced prostate cancer who are receiving a targeted radiation therapy (177Lu-vipivotide tetraxetan). The goal…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This study enrolls 950 men with suspected but undiagnosed prostate cancer who are scheduled for a biopsy. Researchers will compare the accuracy of prostate MRI against a panel of blood and urine biomarkers (PCA3, PSA, TMPRSS2:ERG) in detecting clinically significant prostate canc…

This study tests whether an upright MRI (where you sit) can detect prostate cancer as well as the standard closed MRI and PSA blood test. About 550 men at risk for prostate cancer will get both types of MRI and answer comfort questionnaires. The goal is to see if the upright MRI …

This study compares two prostate biopsy techniques—cognitive-targeted and MRI-ultrasound fusion—to see which detects prostate cancer more accurately. About 80 men with elevated PSA and suspicious MRI findings will participate. Results may help doctors choose the best biopsy metho…

This study compares a new PET-CT scan (FCH-PET-CT) to standard imaging (bone scan and MRI/CT) to see which better finds cancer that has spread outside the pelvis in men with prostate cancer and specific DNA repair gene mutations. About 50 men with these mutations will be enrolled…

This study tests whether a special PET/MRI scan (PSMA) can find aggressive prostate cancer better than standard biopsies in men with a negative MRI but still suspected of having cancer. One hundred men will receive both the new targeted biopsies and standard systematic biopsies. …

This study tests a new strategy for diagnosing prostate cancer in men with moderate risk. Instead of immediately doing a biopsy, doctors will monitor them with regular PSA tests and MRI scans. The goal is to see if this approach can safely delay biopsies, avoid unnecessary proced…

This study tests a new type of MRI scan to see if it can diagnose prostate cancer more accurately than standard MRI. Researchers will compare the new scan's results with tissue samples from biopsies or surgery. The goal is to find better ways to detect cancer without unnecessary …

This study is testing whether a simpler type of MRI, called biparametric MRI (bpMRI), can improve prostate cancer screening in men at high risk, such as Black men or those with a family history of the disease. The researchers will combine bpMRI with standard PSA blood tests to se…

This study aims to see if a new type of PET scan (called 68Ga-XACP3) can find prostate cancer tumors as well as or better than the current standard scan (68Ga-PSMA). About 60 adults with newly diagnosed, suspected recurrent, or treated prostate cancer will receive both scans. The…

This study tests a community-based program to help underserved adults get screened for breast, lung, and prostate cancers. Researchers will work with local resource spots to offer screenings and follow-up care. The goal is to see if this approach increases screening rates and cat…

This study is testing a new way to screen for aggressive prostate cancer. Researchers will give 1,500 men aged 40-69 a genetic risk score, a PSA blood test, and a special MRI. The goal is to see if combining genetic risk with MRI can better identify high-grade cancers that could …

This study is testing whether a new MRI technique using a substance called hyperpolarized pyruvate gives consistent results in people with solid tumors. About 109 participants will have two special MRI scans to see if the images are reproducible. The goal is to improve how doctor…

This study tests a new contrast agent called Gadopiclenol (Elucirem) for MRI scans of the prostate. The goal is to see if it makes aggressive prostate cancers stand out more clearly, helping doctors decide who needs a biopsy. About 150 men scheduled for a prostate MRI will receiv…

This study will test whether a special type of scan called PSMA PET/MRI can find prostate cancer that comes back after a treatment called High-Intensity Focused Ultrasound (HIFU) better than a standard MRI. About 60 men who had HIFU for prostate cancer will get both scans one yea…

This study tests a new FDA-approved device called the Histolog Scanner, which takes high-resolution images of the prostate surface right after it is removed during surgery. The goal is to see if this faster method can save more than 20 minutes compared to the standard lab process…

This study compares two ways to use MRI images during prostate biopsy: software fusion (computer-assisted) and cognitive fusion (doctor's visual estimate). Over 1,300 men with suspicious prostate lesions will be randomly assigned to one method. The goal is to see which technique …

This study compares a new radioactive tracer, 68Ga-P16-093, with the standard tracer 68Ga-PSMA-11 for PET/CT imaging in 50 men with untreated prostate cancer. The goal is to see which tracer better detects tumors and their spread. Participants will receive both tracers within a w…

This phase 3 study is testing a radioactive tracer called 18F-PSMA-1007 for PET/CT scans in 2800 men with prostate cancer. The goal is to see if it can safely and accurately detect cancer that has spread, especially in men with rising PSA levels after treatment. Participants will…

This Phase 3 trial is testing whether combining a special PET scan (PSMA PET) with MRI can detect prostate cancer better than standard methods. About 204 men with suspected prostate cancer will receive the combined imaging, and results will be compared to biopsy findings. The goa…

This study tests a software tool called TRAQinform Theranostics that analyzes PET/CT scans to help doctors decide on treatment for metastatic prostate cancer. Researchers will see if having this extra information changes the treatment plan. The study involves 32 patients starting…

This early-stage trial is testing a new imaging agent called Flotufolastat F-18 in 6 healthy Chinese adults. The tracer is designed to light up prostate cancer cells during PET scans. Researchers are checking how safe it is, where it goes in the body, and how much radiation it gi…

This study aims to find the best way to encourage Black or African American men aged 40 and older to get screened for prostate cancer. Researchers are comparing three approaches: passive education using QR codes in barbershops, active help from a community navigator, and communit…

This early-phase study is testing whether lisinopril, a widely used blood pressure drug, can prevent urinary side effects in men receiving radiation for prostate cancer. Thirty men with non-metastatic prostate cancer will take one of three daily doses (5, 10, or 20 mg) during the…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…

This study is for men with low- to intermediate-risk prostate cancer. It compares giving a lower radiation dose to some parts of the prostate versus the same dose to the whole prostate. The goal is to see if the lower dose reduces short-term urinary side effects. About 54 people …

This study tests a device called the Axonics SNM System, which uses mild electrical pulses to calm the nerves that control the bladder. It is for men with overactive bladder, including those with urgency incontinence or frequent urination. The trial will enroll 150 men and track …

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This study looks at whether taking creatine supplements while doing supervised weight training for 12 weeks can help men with prostate cancer who are on hormone therapy (ADT) maintain or improve their muscle mass, strength, and physical function. ADT often causes muscle loss and …

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests whether applying a powder called ARISTA AH during robotic prostate removal can reduce blood loss and help preserve erectile function. About 362 men with prostate cancer will be randomly assigned to receive the powder or standard care. The goal is to see if the po…

This study tests whether adding acupuncture and acupressure to standard anti-nausea medicine can better reduce chemotherapy-induced nausea. About 90 cancer patients with ongoing nausea will be split into two groups: one gets the extra acupuncture, the other gets medicine alone. T…

This study tests whether a rectal indomethacin suppository given right after surgery can prevent or reduce bladder discomfort caused by a urinary catheter in men undergoing laparoscopic radical prostatectomy. About 130 participants will be randomly assigned to receive either the …

This study looks at whether men recovering from robotic prostate surgery can manage pain without automatically receiving opioid painkillers. Half of the 300 participants will get a standard pain plan plus an opioid prescription, while the other half will get only the pain plan an…

This study looks at whether adding local anesthesia (numbing medicine) during a prostate biopsy, while patients are already sedated, reduces pain after the procedure. About 800 men will take part. The goal is to see if this simple change can lower pain scores, cut down on painkil…

This study tests whether wearing a virtual reality (VR) headset during daily radiation therapy can help manage anxiety in people with prostate, breast, lung, or head and neck cancer. About 54 patients will use a Meta Quest 2 headset during their treatments, and researchers will t…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study looks at whether saving a small extra artery to the penis during robotic prostate cancer surgery can help men recover erections. About 1 in 3 men have this artery, and the study will use MRI scans to find it before surgery. Researchers will follow 20-40 men for a year …

This pilot study is testing a new way to give radiation for prostate cancer that uses an MRI machine to guide the treatment. The goal is to give a lower dose of radiation to the whole prostate while giving a higher dose only to the main tumor, which may reduce side effects like u…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This pilot study is testing whether intermittent fasting (with an optional plant-rich diet) is practical and helpful for 30 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). The main goal is to see if patients can stick with the diet, not …

This study tests a 12-week home-based rehabilitation program for men with advanced prostate cancer living in rural areas. The program includes exercise and support delivered via video calls to help manage side effects from hormone therapy and improve quality of life. About 30 par…

This study compares two methods to help men regain erectile function after prostate cancer surgery. About 224 men who had surgery within the past 9 months will take part. The goal is to see which approach works better for sexual rehabilitation.

This study is testing a mobile health app designed to help Black men who have had prostate cancer feel better and track their quality of life. About 248 participants will use the app and share their feedback on how easy it is to use and how it affects their physical, emotional, a…

This study is testing whether giving a lower dose of radiation in just two sessions can reduce side effects for men with intermediate-risk prostate cancer. All participants will be treated on a special MRI-guided machine (MR-Linac) that adapts the radiation daily. The main goal i…

This study tests a program called PC-PEP in 400 men who have had prostate cancer. The program teaches life skills and healthy habits to reduce side effects like incontinence and sexual problems, and to improve mental health, fitness, and overall quality of life. Participants will…

This study compares adaptive radiotherapy (ART) with conventional radiotherapy in 188 men with prostate cancer. ART adjusts the radiation beam daily to account for changes in organ position, potentially reducing digestive and urinary side effects. Patients will report their sympt…

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…

This study tests whether a 12-week home-based exercise program can improve heart and lung fitness in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). Sixty men will either follow the exercise program or receive healthy living education. The goal…

This study looks at whether a 6-month home exercise and nutrition program can improve thinking and physical abilities in cancer survivors aged 65 and older, along with their support person. About 1,500 participants will be assigned to either a virtually supervised or unsupervised…

This early-phase study tests whether a weight-loss drug called tirzepatide can help overweight or obese men with intermediate-risk prostate cancer lose weight before their prostate removal surgery. The study will enroll 30 participants and focus on safety and how well the program…

This study tests a new feature on the da Vinci 5 surgical robot that gives surgeons a sense of touch during prostate cancer surgery. 60 patients will take part, with surgeons randomly using the force feedback on or off. The goal is to see if this helps surgeons learn faster and r…

This trial tests whether a structured nurse-led education session before prostate cancer surgery, plus a direct referral to pelvic floor physiotherapy, can reduce urinary incontinence afterward. Eighty men having their prostate removed will be randomly assigned to either standard…

This study is testing a program called MyCarePulse and ASCENT to help cancer patients overcome food-related challenges. About 100 adults recently diagnosed with certain cancers will either receive the program or standard care. The goal is to see if the program improves food secur…

This trial compares two types of radiation therapy for low-risk prostate cancer: SBRT (a precise, high-dose external beam treatment) and low-dose rate brachytherapy (implanting radioactive seeds). The goal is to see which causes fewer urinary and bowel side effects and leads to a…

This study compares two types of radiation for prostate cancer: one that targets only the tumor and one that treats the whole prostate. The goal is to see if the focused approach causes fewer short-term side effects like bladder or bowel problems. About 150 men with intermediate-…

This study tests a newer type of radiation therapy that adjusts to daily changes in a patient's body shape. The goal is to safely use smaller treatment areas to reduce side effects like bladder and bowel problems. About 280 adults with pelvic cancers (prostate, bladder, rectal, a…

This study tests a 12-week telehealth exercise program for rural cancer survivors who have ongoing fatigue after treatment. Participants receive personalized exercise sessions via video calls and an app, and provide small blood samples at home. The goal is to see if the program r…

This study tests whether a digital support program can help people with breast, prostate, or colorectal cancer reduce the time they spend sitting during their treatment. The goal is to improve their well-being and lower future health risks. About 172 participants will use an acti…

This study tests whether a digital exercise program with online group sessions can help prostate cancer patients on hormone therapy exercise more regularly. 160 participants will either get standard care or standard care plus the digital program. Adherence is tracked with a weara…

This study tests whether adding neuromuscular electrical stimulation to a regular exercise program can help men on long-term hormone therapy for prostate cancer maintain leg muscle strength. About 48 participants will be assigned to either exercise alone or exercise plus electric…

This study tests whether using a virtual reality headset, an aromatherapy patch, or both can help men feel less pain, fear, and embarrassment during a prostate biopsy. About 208 men will be randomly assigned to one of four groups: VR, aromatherapy, both, or standard care. The goa…

This study tests whether a shorter, more intense radiation course (SBRT, about 2 weeks) is gentler on quality of life than the standard 4-week course for men with prostate cancer who have had their prostate removed. About 136 men will be randomly assigned to one of the two schedu…

This study tests the ApricityCare program, which helps people with metastatic cancer and their doctors spot treatment side effects early. The goal is to manage these side effects quickly so patients can stay on their cancer therapy longer. About 425 adults starting systemic cance…

This study tests a precise radiation technique called neurovascular-sparing SBRT for men with prostate cancer. The goal is to see if customizing each treatment session based on MRI images can better protect the nerves and blood vessels needed for erections, compared to standard r…

This study tests a technique called 'Spot Delete' during pencil beam scanning proton therapy for low- and intermediate-risk prostate cancer. The goal is to reduce side effects like diarrhea, rectal bleeding, and urinary problems by preventing proton beams from stopping in sensiti…

This study tests whether 4-aminopyridine (4-AP) can help men recover faster from nerve damage caused during prostate cancer surgery. About 70 men aged 45-75 with early-stage prostate cancer will take the drug or a placebo after their operation. The goal is to see if it improves b…

This study is testing SHAReClinic, a national virtual clinic that provides sexual health education and counselling to prostate cancer patients and their partners. Researchers will enroll 575 people across Canada to see if the program improves sexual function, reduces distress, an…

This pilot study is testing whether a web-based insomnia treatment called SHUTi can help Black/African American prostate cancer survivors sleep better. Forty participants will be randomly assigned to either the SHUTi program or an educational website. The study will check if the …

This study looks at whether daily text message reminders to do pelvic floor exercises can help men recover bladder control faster after prostate surgery. About 132 men who are planning to have prostate surgery will be split into two groups: one gets the text reminders, the other …

This trial compares two different schedules of MRI-guided radiation for men with low or favorable intermediate risk prostate cancer. One group gets the standard five sessions, the other gets just two sessions. The goal is to see if the shorter course can maintain cancer control w…

This study looks at whether a special MRI scan (mpMRI) can better monitor prostate cancer in men who choose active surveillance instead of immediate treatment. About 500 men with low-risk prostate cancer will get regular MRIs, biopsies, and blood tests over several years. The goa…

This study explores whether a 7-day water-only fast or ketone supplements are safe and doable for men with prostate cancer. The idea is that fasting may change the body's metabolism and boost immune cells to better attack cancer. Researchers will track side effects and how many p…

This study is testing a web-based tool called CARE that gives cancer patients information about treatment costs, health insurance, and financial resources. About 430 adults with gynecologic, prostate, lung, or colorectal cancer will use the tool to see if it helps them feel more …

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study looks at heart-related side effects in older men with advanced prostate cancer treated with enzalutamide or darolutamide. Researchers will analyze existing health records from 3,000 men aged 55 and older to compare rates of heart attacks, strokes, and heart-related dea…

This study tests whether a short video can help more minority patients with prostate cancer join clinical trials. Researchers at LBJ Hospital will show the video to 60 patients and ask them questions before and after. The goal is to find a simple way to make cancer research more …

This study tests an artificial intelligence (AI) tool designed to help doctors and physicists review radiation treatment plans for cancer patients before therapy begins. The AI highlights differences in how providers plan treatments and flags potential warning signs, aiming to re…

This study aims to help African American cancer survivors learn about and get genetic testing for hereditary cancer risks. Researchers are adapting an online educational program to be culturally relevant, with input from community leaders and genetics experts. About 85 participan…

This study tests a digital app called the Genetics Adviser for Mainstream Care (GA-Mainstream) that educates cancer patients about genetic testing and delivers their results. Researchers want to see if using the app reduces distress and improves the patient experience compared to…

This study follows 2,000 men with prostate cancer who have certain gene mutations. Researchers will track their health over many years to see how these genes relate to cancer growth, treatment response, and survival. Participants do not need to visit the hospital regularly; most …

This study is gathering medical records and imaging data from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in scans that could help diagnose and treat the disease more effectively. No new drugs or procedures are being tested.

This study compares two imaging methods—micro-ultrasound and MRI—for monitoring prostate cancer in men on active surveillance. Researchers will perform biopsies guided by each technique to see which better detects cancer progression. The goal is to determine if micro-ultrasound c…

This study uses detailed MRI scans and targeted biopsies to investigate why some prostate cancers come back after radiation therapy. Researchers will follow 300 men who are scheduled for radiation or whose cancer has returned after earlier treatment. The goal is to better underst…

This study collects blood, urine, saliva, and tumor tissue from 3,000 men with prostate cancer to investigate genetic changes that cause the disease. Participants may also undergo imaging and answer quality-of-life questions. The goal is to better understand prostate cancer and l…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study observes 400 men in Russia with aggressive, high-volume metastatic hormone-sensitive prostate cancer. Researchers will track which treatments doctors use (like hormone therapy, chemotherapy, or radiation) and test blood samples for genetic mutations. The goal is to und…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This registry gathers real-world information from thousands of men treated with high-intensity focused ultrasound (HIFU) for prostate cancer using the Focal One device. The goal is to monitor safety and track cancer control through routine PSA tests and MRI scans. By collecting d…

This study looks at how the pressure settings on a breathing machine during robot-assisted prostate surgery affect the lungs afterward. Researchers will use lung ultrasound to check for changes in lung health. The goal is to find better ways to set the breathing machine to protec…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study looks at how much fluid patients should receive during robotic prostate surgery. It compares a standard approach with a more restricted one, using a non-invasive heart monitor to guide decisions. The goal is to see which method keeps tissues better perfused, measured b…

This study looks at whether men with prostate cancer who have hot flashes from hormone therapy will consistently wear a smartwatch to track their symptoms. For 4 weeks, 18 participants will wear the watch, log hot flashes by pressing a button, and complete daily surveys. The goal…

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid, prostate, or neuroendocrine cancers. The goal is to provide researchers with valuable data to better understand these treatments. No new …

This study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…

This study compares two levels of patient navigation—high-intensity versus low-intensity—to see which helps more people with prostate or kidney cancer enroll in clinical trials. About 90 participants will be randomly assigned to receive either extra support from a patient navigat…

This study is a registry that collects information from 1,000 men with prostate cancer who receive focal therapy using high-intensity focused ultrasound (HIFU) or irreversible electroporation (IRE). No new treatment is given—researchers simply record patient details, disease feat…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study is for men with intermediate- or high-risk prostate cancer who will receive hormone therapy and radiation. Researchers want to see if using a special PET scan (PSMA PET) during hormone therapy can help doctors better target remaining cancer with radiation while avoidin…

This study follows 106 men who have had surgery for prostate cancer to see how well they recover bladder control, sexual function, and overall health. Participants will receive standard care plus optional exercise programs. The goal is to better understand recovery timelines and …

This study brings together a panel of prostate cancer specialists to agree on the most important pieces of information that should be included in medical records. The goal is to create a standard way to report key data, making it easier for doctors to manage patients from diagnos…

This study follows 80 men aged 65 and older with prostate cancer in Ireland. Researchers will measure frailty, daily functioning, and quality of life over 12 months. The goal is to see how well current frailty screening tools predict health outcomes, helping doctors tailor care f…

This study follows men with low-risk prostate cancer who have chosen active surveillance—monitoring the cancer over time rather than treating it right away. Researchers will collect data for years to learn which signs predict that the cancer may become aggressive. The goal is to …

This study is a large international registry that will follow at least 5,000 men with advanced prostate cancer for five years or more. Researchers will collect detailed information on treatments, side effects, and quality of life to see which approaches work best. The goal is to …

This study is testing whether an 8-minute educational video can effectively prepare cancer patients for genetic testing, compared to standard genetic counseling. Over 1,000 adults with various cancers will participate. The goal is to see if the video is acceptable and improves un…

This study follows 837 men with high-risk prostate cancer who choose either robot-assisted surgery or radiation therapy (with or without hormone therapy). Researchers will compare quality of life, side effects, and cancer control over time. The goal is to help patients and doctor…

This study tests a new tool called TRTRM that predicts which older cancer patients are at high risk for severe side effects from treatment. Researchers will use the tool to adjust drug doses and monitoring for patients aged 65 and older with solid tumors. The goal is to see if th…

This study is testing a special MRI scan that uses a substance called hyperpolarized pyruvate to see how well it can monitor prostate cancer in patients who are not receiving treatment. About 60 men with low- to intermediate-risk prostate cancer will be scanned to measure how the…

This study looks at whether artificial intelligence (AI) can help radiologists find prostate cancer on MRI scans. About 150 men aged 55-80 who are scheduled for a prostate biopsy will take part. The AI software will be compared to radiologists reading the scans alone. The goal is…

This study looks at how well a short course of hormone therapy (ADT) works in men with high-risk prostate cancer that hasn't spread. Researchers use a special PET/CT scan to measure changes in cancer activity before and after treatment. About 50 men will take part, and they will …

This study aims to validate a gene test that identifies oxygen-starved (hypoxic) tumours in bladder and prostate cancer patients. About 30 participants will provide tumour samples and blood, and some will have MRI scans. The goal is to see if this test can help doctors choose mor…

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study looks at whether exposure to chlordecone, a pesticide banned in 1993 but still present in the environment, is linked to prostate cancer in men from Martinique. Researchers will compare 3600 men with and without prostate cancer, measuring chlordecone levels in blood and…

This study is testing a software tool that uses DNA from a blood sample to predict the risk of blood clots returning in people with cancer who have finished 3-12 months of blood thinner treatment. The goal is to see if a low-risk result means it's safe to stop blood thinners with…

This study is for people already in the SYNERGY-201 trial, which tests a drug combination for prostate cancer. Researchers want to see if a marker called CXCR2 can predict who will respond well to the treatment. Blood samples and optional tumor biopsies will be collected over tim…

This study is testing whether an artificial intelligence (AI) system can automatically measure the amount of cancer seen on PSMA PET-CT scans in 1,500 men with prostate cancer. The AI will calculate tumor volume and uptake, and researchers will see if these measurements can predi…

This study compares three surgical methods for removing the prostate in men with prostate cancer: robot-assisted laparoscopy, standard laparoscopy, and open surgery. Researchers will track urinary and erectile function before and after surgery in 2,000 participants. The goal is t…

This study aims to improve treatment for aggressive prostate cancer by growing 3D mini-tumors from patient samples in the lab. Researchers will compare two techniques to see which better predicts how a patient's cancer will respond to radiation or drugs. The goal is to help docto…

This study aims to describe the characteristics of prostate cancer in Algeria, including patient demographics, symptoms, diagnosis methods, and treatments. Researchers will collect data from 2,000 men aged 19 and older with confirmed prostate cancer. The goal is to better underst…

This study is developing and testing an educational tool to help men aged 65 and older with prostate cancer decide with their doctors whether to reduce the frequency of follow-up tests like biopsies. The tool is being tested with 45 participants, including patients, caregivers, a…

This study is creating and testing a simple educational tool to help Black or African American men with metastatic prostate cancer understand genetic testing for their tumors. The goal is to make counseling fairer and easier to use. About 80 men will take part, first giving feedb…

This study looks at whether giving men with low-risk prostate cancer two extra tests—a genomic test (GPS) and a special MRI—helps them stick with active surveillance (monitoring instead of immediate treatment). Researchers will track 222 men for 18 months to see if these tests im…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study is testing whether two types of PET scans can better detect where prostate cancer has spread in the body. About 300 men with prostate cancer that is getting worse will receive injections of a radioactive tracer and then be scanned. The goal is to see if these scans are…

This study looks at how much of the radioactive drug Pluvicto reaches tumors and organs in patients whose kidneys or bone marrow are not working well. About 25 people will be enrolled to check for side effects and safety. The goal is to better understand dosing in these patients,…

This study follows 64 men with localized prostate cancer who undergo laparoscopic radical prostatectomy (keyhole surgery to remove the prostate). The goal is to track any complications that occur from the day of surgery up to 30 days later. By understanding how often problems hap…

This study looks at how SPECT imaging can help doctors measure the amount of radiation reaching healthy organs during certain cancer treatments. About 80 adults with advanced prostate or other cancers will get extra SPECT scans before and after their standard radiation therapy. T…

This study compares regular MRI scans to standard care for men with low- to medium-risk prostate cancer who choose active surveillance (monitoring instead of immediate treatment). The goal is to see if MRIs can detect cancer progression earlier and more accurately, potentially re…

This study aims to see if specially trained radiographers can make decisions about prostate MRI scans as well as radiologists. The goal is to reduce the need for contrast injections and extra scans, making care faster and more efficient. The study will involve 1600 patients and c…

This study looks at whether a new telehealth program can help people with breast or prostate cancer get care from home instead of traveling to the doctor's office. About 1,750 patients at Memorial Sloan Kettering will take part. The goal is to see if this approach reduces the num…

This study looks at how the head-down position and gas used during robotic prostate surgery affect pressure inside the eye. Researchers will measure eye pressure with a simple ultrasound in 50 men having either robotic or open prostate surgery. The goal is to understand these cha…

This study looks at why some prostate cancers stop responding to a type of targeted radiation therapy called PSMA radioligand therapy. Researchers will use scans and tumor biopsies from 125 people starting this treatment to measure radiation doses and check gene activity linked t…

This study compares two ways to check men with high PSA levels for dangerous prostate cancer: giving everyone an MRI first, or using a risk calculator to decide who needs an MRI and biopsy. The goal is to see if the calculator method catches just as many serious cancers while red…

This study is a registry that will follow about 5,000 men with prostate cancer that has come back or spread. It aims to record which treatments doctors actually use in routine care and how the disease progresses over time. Participants are grouped by their cancer stage, from PSA …

This study looks at how to help veterans with advanced prostate cancer make informed decisions about precision oncology tests, which use genetic information to guide cancer care. Researchers will develop and test a decision support tool to reduce confusion and address racial gaps…

This study is collecting blood samples and imaging scans from 144 prostate cancer patients before, during, and after standard radiation therapy. Researchers want to see if changes in circulating tumor cells and MRI/PET imaging features can help predict how well the cancer respond…

This study is a large registry that will follow about 8,000 cancer patients who receive radiation therapy using a special machine called an MR-Linac, which combines an MRI scanner with a radiation beam. The goal is to learn how well this technology works for different cancers, in…

This study is creating a large registry of 1,500 men with newly diagnosed prostate cancer. Researchers will track their health, side effects, and quality of life over time to better understand how different treatments affect patients. The goal is to build a platform for future st…

This study looks at 60 men with prostate cancer who had a high-risk genetic test (Decipher score >0.45). They will get a special PSMA-PET scan two years after their initial treatment to see if the cancer has spread. The goal is to learn how well the genetic test predicts early me…

This study looks at how urological diseases and their treatments impact patients' work life. Researchers will survey 2,000 adults admitted to a hospital in Poland, focusing on those having major cancer surgeries or stone procedures. Participants will be followed for 6 months to t…

This study looks at tumor samples from 150 Native American patients with prostate cancer. Researchers want to find genetic differences that may affect how the cancer grows and responds to treatment. The goal is to learn more so that future care can be better tailored for this gro…

This study looks at whether a person's inherited genetic risk can predict if they have prostate cancer. Researchers will compare the genetic risk scores of 1,000 men aged 40-69 who are already scheduled for a prostate biopsy. The goal is to see if men with higher genetic risk are…

This study is testing new MRI techniques to see if they can detect prostate cancer better than current scans. Researchers will compare different mathematical models of tissue structure with detailed lab analysis of removed prostate tissue. The goal is to improve diagnosis without…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning earlier than standard scans. About 100 people with different solid tumors will give blood samples after treatment. The goal is to see if early detection can lead to better treatm…

This study uses special PET/CT scans to see how advanced prostate cancer becomes resistant to newer hormone therapies like enzalutamide or abiraterone. Researchers will track changes in cancer lesions over time in 25 participants. The goal is to better understand resistance patte…

This study compares two ways to guide prostate biopsies using MRI: cognitive-guided (doctor mentally aligns images) and MRI-ultrasound fusion (computer overlays images). It aims to see which method finds more clinically significant prostate cancers. The trial will enroll 1,250 me…

This study is testing how two types of Mediterranean diets (lower-carb or low-fat) affect metabolism in men with early prostate cancer who are not yet receiving treatment. Researchers will measure changes in prostate tissue and blood. The goal is to understand if diet can influen…

This study follows 100 men with low- or very low-risk prostate cancer who choose active surveillance instead of immediate treatment. Researchers will use questionnaires, exams, biopsies, and MRIs every 6 months to 2-3 years to monitor disease progression over 5 years. The goal is…

This study is testing whether educational videos and brochures can help Spanish-speaking Latinx patients with breast or prostate cancer better understand their radiation therapy and clinical trials. About 194 participants will watch videos or read brochures, then answer questions…

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This study looks at two methods of monitoring blood pressure during robot-assisted prostate removal surgery. The goal is to see if using a standard arm cuff (oscillometric) is as good as using a small tube in an artery (intraarterial) at preventing dangerously low blood pressure …

This study follows 200 men with low-risk prostate cancer who are on active surveillance (monitoring instead of immediate treatment). Researchers want to see if men with a higher genetic risk for prostate cancer are more likely to have their cancer progress over time. The goal is …

This study is testing whether dried blood spots from a finger prick can reliably measure levels of common prostate cancer drugs. Researchers will compare results from the finger-prick method with standard blood tests in 100 patients. If the new method works, it could make drug mo…

This study creates a database to track men with prostate cancer who choose prostate ablation—a minimally invasive procedure to destroy cancer cells. Researchers will collect information from medical records on cancer control, side effects, and quality of life for up to 3,000 part…

This study looks at how much radiation reaches tumors and healthy organs during a treatment called 177Lu-PSMA-617 for advanced prostate cancer that has spread. Researchers want to see if the radiation dose can predict how well the treatment works and what side effects might occur…

This study looks at whether an educational supplement—using models and props during a face-to-face interview—can help African-American men newly diagnosed with early-stage prostate cancer better understand their treatment options and side effects. Researchers will interview 210 p…

This study aims to develop and test an AI model that analyzes prostate MRI scans to predict whether a cancer is aggressive (clinically significant). Researchers will use data from 3,000 patients who had both an MRI and a biopsy. The goal is to create a tool that helps doctors dec…

This study looks at whether a special PET scan (PSMA-PET) and a blood test (ctDNA) can detect prostate cancer progression earlier than standard PSA tests. About 50 adults with prostate cancer that has spread to a few spots will get radiation therapy. Researchers will check scans …

This study is looking for substances in urine that could help predict how well prostate cancer treatments work. Researchers will collect urine samples from 360 men with prostate cancer who are receiving standard treatments like surgery, radiation, chemotherapy, or hormone therapy…

This study looks at anxiety levels in men with low-risk prostate cancer who are closely monitored instead of receiving immediate treatment, and also checks how their partners are doing. Researchers will use questionnaires to measure anxiety and find out what factors might predict…

This study tests a new imaging method called iRAI that uses sound waves to monitor proton radiation delivery in real time for prostate cancer patients. Researchers will compare the actual radiation dose measured by iRAI with the planned dose from CT scans. The goal is to see if i…

This pilot study aims to see if a brief educational session can increase the number of Black men with aggressive prostate cancer who complete genetic testing. Researchers will enroll 50 men who identify as Black or multiracial and have high-risk prostate cancer. Participants will…

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…

This study checks if a new PET-CT scanner (RefleXion X1) can see prostate cancer tumors as well as the standard scanner does. About 25 men with prostate cancer who are already getting a standard PET scan will get an extra scan on the new machine. The goal is to see if the new sca…

This study looks at whether a special blood test can find tiny bits of tumor DNA left after prostate cancer surgery. The goal is to see if this test can better predict if the cancer will come back early in high-risk patients. About 50 men with high-risk prostate cancer will give …

This study looks at whether a genetic test can better identify which men ages 55-69 are at risk for serious prostate cancer and which are not. Current screening methods often lead to unnecessary biopsies. The goal is to see if using genetic information can help high-risk men get …

This study is creating an artificial intelligence (AI) model that uses MRI scans and tissue samples to predict whether high-risk prostate cancer has spread to nearby lymph nodes. The goal is to help doctors make better treatment decisions without needing extra invasive tests. Abo…

This study looks at whether a genetic test can help decide which men with prostate cancer can safely have a less invasive treatment called focal therapy, which targets only the tumor instead of the whole prostate. Researchers will enroll 130 men and use the test to classify their…

This study aims to build and test an AI-based early warning system to screen men aged 50 and older for prostate and bladder cancer. Researchers will enroll 3,000 male residents of Beijing, measuring PSA levels and using AI to flag high-risk individuals. No drugs or devices are gi…

This study tests a new type of MRI scan that uses a special substance called hyperpolarized pyruvate to see how prostate cancer cells change during radiation therapy. About 161 men with prostate cancer will receive the substance through an IV before their regular MRI scans. The g…

This study is testing whether a special type of MRI scan can show early signs that high-risk prostate cancer is responding to treatment. About 32 men will get the scan before and during therapy, and results will be compared to standard tissue exams after surgery. The goal is to f…

This study is collecting information from 200 men who have had or will have focal therapy for prostate cancer. Focal therapy uses targeted methods like freezing (cryotherapy) or ultrasound (HIFU) to treat only the cancerous part of the prostate. The goal is to understand how thes…

This study looks at whether patient navigators can help African American, Native American, and Hispanic patients complete their radiation therapy for breast or prostate cancer. About 420 participants will fill out surveys before and after treatment to identify barriers and measur…

This study looks at whether a genetic test can help predict prostate cancer risk in men who have or are at high risk for the disease. Researchers will analyze DNA from 3000 men to find rare and common genetic changes linked to prostate cancer. The goal is to see if this informati…

This study tests whether giving doctors and patients a report generated by artificial intelligence can improve how well risks and benefits of prostate cancer treatments are discussed. About 283 men with newly diagnosed prostate cancer and their doctors will be randomly assigned t…

This study tests whether showing surgeons a visual decision-support tool before they meet with patients improves how they discuss risks and benefits of surgery. Up to 20 urologists and 200 patients with prostate or kidney cancer will take part. Researchers will compare conversati…

This study gathers information from medical records of 534 people with metastatic prostate cancer worldwide. It looks at how well different treatments work in everyday practice, including hormone therapy, a radioactive drug called Lutetium-177, and PARP inhibitors. The goal is to…

This study is testing a new fine needle probe that uses light and sound (photoacoustic technology) to measure prostate tissue during a standard biopsy. The probe is inserted like a regular biopsy needle but does not remove tissue. Researchers want to see if it can reliably tell t…

This study is testing a blood test that looks for tiny pieces of prostate cancer cells floating in the bloodstream. The goal is to see if the number of these cells can tell doctors how advanced the cancer is and if it comes back after surgery. About 200 men with early-stage prost…

This study looks at whether certain substances in the blood can help doctors predict how prostate cancer patients will respond to their treatment. Researchers will collect blood samples from 600 men at different stages of prostate cancer and analyze them for biomarkers. The goal …

This study looks at how hormone treatments for prostate and breast cancer affect sleep quality. Researchers will monitor 60 patients using sleep tests, activity trackers, and questionnaires before treatment starts, then again at 6 and 12 months. The goal is to understand if these…

This study is testing whether a blood test can detect prostate cancer cells that have spread, similar to a special PET scan. Researchers will take blood samples from 80 prostate cancer patients before their PET scans and compare the results. If the blood test works well, it might…

This study looks at how well African American and rural White men understand genetic testing for prostate cancer. Researchers will use educational videos and surveys to measure genetic literacy and knowledge. The goal is to help men make more informed decisions about their prosta…

This study is building a collection of prostate tissue samples from people who carry certain gene mutations (like BRCA1/2) that raise their risk for aggressive prostate cancer. Researchers will compare these samples with those from people without the mutations to learn how the ca…

This study compares a chatbot to standard care to see which better helps Black cancer survivors learn about and request genetic testing for hereditary cancer. About 428 participants will be randomly assigned to either group. The goal is to reduce disparities in genetic testing an…

This study is collecting blood samples from 24 men with high-risk localized prostate cancer before they have their prostate removed. Researchers will use a highly sensitive test to look for tiny bits of tumor DNA floating in the blood. The goal is to see if this DNA can help pred…

This study aims to create and improve educational materials about genetic testing for cancer patients from diverse backgrounds. Researchers will interview 445 people with breast, ovarian, pancreatic, prostate, or colorectal cancer who speak English, Spanish, or Haitian Creole. Th…

This study follows 120 men with advanced prostate cancer to see if markers in their blood can predict how well they respond to hormone therapy. Researchers will collect blood samples and compare markers between those who respond well and those who don't. The goal is to develop a …

This study aims to understand the genetic and molecular drivers of breast and prostate cancer in 1,500 people of African ancestry. Participants from nine countries will provide blood and tumor samples for genetic testing. The goal is to identify inherited mutations and other geno…

This study looks at how cancer affects not just patients, but their entire family. Researchers will survey 240 Danish patients with breast, prostate, colorectal cancer, or lymphoma, along with their caregivers. They will measure family health, stress, depression, and quality of l…

This study looks at whether elderly men (70+) with prostate cancer who have been on hormone therapy for over 3 years can safely stop it. Researchers will check if their testosterone stays at castrate levels without ongoing treatment. The goal is to see if stopping is feasible and…

This study will follow 300 men with early-stage prostate cancer who choose to be treated with high-intensity focused ultrasound (HIFU). Researchers will collect data on side effects, cancer control, and urinary and sexual function over time. The goal is to better understand how w…

This study tests whether a smartphone app called Connect2Care can help African American men ages 45-69 learn about prostate cancer and feel ready to take a PSA screening test. About 266 men in Oklahoma who haven't been screened recently will use either the Connect2Care app or a s…

This study follows over 4,000 men with prostate cancer, some with rare gene mutations (BRCA1, BRCA2, HOXB13, Lynch Syndrome) and some without. Researchers will track their treatment results and survival over time. The goal is to learn whether these mutations affect how the diseas…

This study is creating a database to track what happens to men with localized prostate cancer who choose cryotherapy (freezing the tumor). Researchers will record side effects and how long it takes for PSA levels to rise again. Up to 1,000 men will be followed over time to gather…

This study is testing whether giving breast, prostate, or colorectal cancer survivors a personal referral to a tailored nutrition and exercise program helps them eat better and move more. Participants will use a Fitbit to track activity and sleep, and attend group nutrition sessi…

This study will enroll 5,500 men with high-risk prostate cancer to analyze their tumors at the molecular level. Researchers hope to find biomarkers that predict which treatments work best. Participants will receive standard care, and the study will not test any new drugs.